{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:36:55Z","timestamp":1794620215818,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41440-025-02229-5","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T02:53:47Z","timestamp":1748400827000},"page":"2209-2217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Renin-angiotensin-aldosterone system and its relation to hypertension"],"prefix":"10.1038","volume":"48","author":[{"given":"Shin-ichiro","family":"Miura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshino","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Seumatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"2229_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/1753944707082697","volume":"1","author":"A Whaley-Connell","year":"2007","unstructured":"Whaley-Connell A, Pavey BS, Chaudhary K, Saab G, Sowers JR. Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection. Ther Adv Cardiovasc Dis. 2007;1:27\u201335.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2229_CR2","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.3390\/ijms25074035","volume":"25","author":"SH Ksiazek","year":"2024","unstructured":"Ksiazek SH, Hu L, And\u00f2 S, Pirklbauer M, S\u00e4emann MD, Ruotolo C, et al. Renin-angiotensin-aldosterone system: from history to practice of a secular topic. Int J Mol Sci. 2024;25:4035 https:\/\/doi.org\/10.3390\/ijms25074035.","journal-title":"Int J Mol Sci"},{"key":"2229_CR3","doi-asserted-by":"publisher","first-page":"28511","DOI":"10.1074\/jbc.270.48.28511","volume":"270","author":"K Noda","year":"1995","unstructured":"Noda K, Saad Y, Karnik SS. Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. J Biol Chem. 1995;270:28511\u20134.","journal-title":"J Biol Chem"},{"key":"2229_CR4","doi-asserted-by":"publisher","first-page":"16435","DOI":"10.1021\/bi961593m","volume":"35","author":"K Noda","year":"1996","unstructured":"Noda K, Feng YH, Liu XP, Saad Y, Husain A, Karnik SS. The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. Biochemistry. 1996;35:16435\u201342.","journal-title":"Biochemistry"},{"key":"2229_CR5","doi-asserted-by":"publisher","first-page":"15791","DOI":"10.1021\/bi980863t","volume":"37","author":"YH Feng","year":"1998","unstructured":"Feng YH, Miura S, Husain A, Karnik SS. Mechanism of constitutive activation of the AT1 receptor: influence of the size of the agonist switch binding residue Asn(111). Biochemistry. 1998;37:15791\u20138.","journal-title":"Biochemistry"},{"key":"2229_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00894-005-0049-z","volume":"12","author":"C Baleanu-Gogonea","year":"2006","unstructured":"Baleanu-Gogonea C, Karnik S. Model of the whole rat AT1 receptor and the ligand-binding site. J Mol Model. 2006;12:325\u201337.","journal-title":"J Mol Model"},{"key":"2229_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2174\/1573402054022285","volume":"1","author":"S Miura","year":"2005","unstructured":"Miura S, Fujino M, Saku K. Angiotensin II receptor blocker as an inverse agonist: a current perspective. Curr Hypertens Rev. 2005;1:115\u201321.","journal-title":"Curr Hypertens Rev"},{"key":"2229_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/BF02850335","volume":"21","author":"M Picca","year":"2004","unstructured":"Picca M, Agozzino F, Pelosi G. Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. Adv Ther. 2004;21:76\u201386.","journal-title":"Adv Ther"},{"key":"2229_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S1388-9842(02)00166-6","volume":"4","author":"E Pantev","year":"2002","unstructured":"Pantev E, Stenman E, Wackenfors A, Edvinsson L, Malmsjo M. Comparison of the antagonistic effects of different angiotensin II receptor blockers in human coronary arteries. Eur J Heart Fail. 2002;4:699\u2013705.","journal-title":"Eur J Heart Fail"},{"key":"2229_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1524-6175.2001.01136.x","volume":"3","author":"S Oparil","year":"2001","unstructured":"Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens. 2001;3:283\u201391.","journal-title":"J Clin Hypertens"},{"key":"2229_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/hr.2014.156","volume":"38","author":"T Kushiro","year":"2015","unstructured":"Kushiro T, Kario K, Saito I, Teramukai S, Mori Y, Okuda Y, et al. Effectiveness of olmesartan-based treatment on home and clinic blood pressure in elderly patients with masked and white coat hypertension. Hypertens Res. 2015;38:178\u201385.","journal-title":"Hypertens Res"},{"key":"2229_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/hr.2009.66","volume":"32","author":"M Sugihara","year":"2009","unstructured":"Sugihara M, Miura S, Takamiya Y, Kiya Y, Arimura T, Iwata A, et al. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res. 2009;32:625\u201330.","journal-title":"Hypertens Res"},{"key":"2229_CR13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3109\/10641963.2012.683912","volume":"34","author":"J Morii","year":"2012","unstructured":"Morii J, Miura S, Shiga Y, Sugihara M, Arimura T, Sako H, et al. Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study). Clin Exp Hypertens. 2012;34:342\u20139.","journal-title":"Clin Exp Hypertens"},{"key":"2229_CR14","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2169\/internalmedicine.52.9261","volume":"52","author":"J Morii","year":"2013","unstructured":"Morii J, Miura S, Ike A, Shiga Y, Sugihara M, Iwata A, et al. Comparison of the efficacies of irbesartan and olmesartan after successful coronary stent implantation. Intern Med. 2013;52:713\u20139.","journal-title":"Intern Med"},{"key":"2229_CR15","doi-asserted-by":"publisher","first-page":"888","DOI":"10.14740\/jocmr2768w","volume":"8","author":"K Motozato","year":"2016","unstructured":"Motozato K, Miura SI, Shiga Y, Kusumoto T, Saku K. Efficacy and safety of a single-pill fixed-dose combination of azilsartan and amlodipine. J Clin Med Res. 2016;8:888\u201392.","journal-title":"J Clin Med Res"},{"key":"2229_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/10641963.2015.1060982","volume":"38","author":"K Motozato","year":"2016","unstructured":"Motozato K, Miura S, Shiga Y, Kusumoto T, Adachi S, Inoue T, et al. Efficacy and safety of two single-pill fixed-dose combinations of angiotensin II receptor blockers\/calcium channel blockers in hypertensive patients (EXAMINER study). Clin Exp Hypertens. 2016;38:45\u201350.","journal-title":"Clin Exp Hypertens"},{"key":"2229_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.14740\/jocmr2675w","volume":"8","author":"S Adachi","year":"2016","unstructured":"Adachi S, Miura S, Shiga Y, Arimura T, Kuwano T, Kitajima K, et al. Depressor and anti-inflammatory effects of angiotensin ii receptor blockers in metabolic and\/or hypertensive patients with coronary artery disease: a randomized, prospective study (DIAMOND Study). J Clin Med Res. 2016;8:743\u20138.","journal-title":"J Clin Med Res"},{"key":"2229_CR18","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1536\/ihj.16-026","volume":"57","author":"T Ishida","year":"2016","unstructured":"Ishida T, Miura S, Fujimi K, Ueda T, Ueda Y, Matsuda T, et al. Visit-to-visit variability and reduction in blood pressure After a 3-month cardiac rehabilitation program in patients with cardiovascular disease. Int Heart J. 2016;57:607\u201314.","journal-title":"Int Heart J"},{"key":"2229_CR19","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/01.HYP.0000202568.01167.B6","volume":"47","author":"LJ Appel","year":"2006","unstructured":"Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM, et al. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006;47:296\u2013308.","journal-title":"Hypertension"},{"key":"2229_CR20","doi-asserted-by":"publisher","first-page":"7103","DOI":"10.1074\/jbc.274.11.7103","volume":"274","author":"S Miura","year":"1999","unstructured":"Miura S, Feng YH, Husain A, Karnik SS. Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. J Biol Chem. 1999;274:7103\u201310.","journal-title":"J Biol Chem"},{"key":"2229_CR21","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1001\/archinte.1996.00440150033003","volume":"156","author":"RS Vasan","year":"1996","unstructured":"Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med. 1996;156:1789\u201396.","journal-title":"Arch Intern Med"},{"key":"2229_CR22","doi-asserted-by":"publisher","first-page":"12846","DOI":"10.1074\/jbc.270.21.12846","volume":"270","author":"YH Feng","year":"1995","unstructured":"Feng YH, Noda K, Saad Y, Liu XP, Husain A, Karnik SS. The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism. J Biol Chem. 1995;270:12846\u201350.","journal-title":"J Biol Chem"},{"key":"2229_CR23","doi-asserted-by":"publisher","first-page":"19288","DOI":"10.1074\/jbc.M602144200","volume":"281","author":"S Miura","year":"2006","unstructured":"Miura S, Fujino M, Hanzawa H, Kiya Y, Imaizumi S, Matsuo Y, et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem. 2006;281:19288\u201395.","journal-title":"J Biol Chem"},{"key":"2229_CR24","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.ddtec.2012.05.001","volume":"9","author":"TH Langenickel","year":"2012","unstructured":"Langenickel TH, Dole WP. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today. 2012;9:e131\u2013e9.","journal-title":"Drug Discov Today"},{"key":"2229_CR25","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1124\/dmd.115.068536","volume":"44","author":"J Shi","year":"2016","unstructured":"Shi J, Wang X, Nguyen J, Wu AH, Bleske BE, Zhu HJ. Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation. Drug Metab Dispos. 2016;44:554\u20139.","journal-title":"Drug Metab Dispos"},{"key":"2229_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/clpt.2013.146","volume":"94","author":"O Vardeny","year":"2013","unstructured":"Vardeny O, Tacheny T, Solomon SD. First-in-class angiotensin receptor neprilysin inhibitor in heart failure. Clin Pharm Ther. 2013;94:445\u20138.","journal-title":"Clin Pharm Ther"},{"key":"2229_CR27","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/HJH.0000000000001219","volume":"35","author":"JG Wang","year":"2017","unstructured":"Wang JG, Yukisada K, Sibulo A Jr, Hafeez K, Jia Y, Zhang J. Efficacy and safety of sacubitril\/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. J Hypertens. 2017;35:877\u201385.","journal-title":"J Hypertens"},{"key":"2229_CR28","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41440-021-00819-7","volume":"45","author":"H Rakugi","year":"2022","unstructured":"Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertens Res. 2022;45:824\u201333.","journal-title":"Hypertens Res"},{"key":"2229_CR29","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/hr.2016.72","volume":"39","author":"S Miura","year":"2016","unstructured":"Miura S, Suematsu Y, Matsuo Y, Tomita S, Nakayama A, Goto M, et al. The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line. Hypertens Res. 2016;39:758\u201363.","journal-title":"Hypertens Res"},{"key":"2229_CR30","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004.","journal-title":"N Engl J Med"},{"key":"2229_CR31","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609\u201320.","journal-title":"N Engl J Med"},{"key":"2229_CR32","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ejhf.474","volume":"18","author":"Y Suematsu","year":"2016","unstructured":"Suematsu Y, Miura S, Goto M, Matsuo Y, Arimura T, Kuwano T, et al. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. Eur J Heart Fail. 2016;18:386\u201393.","journal-title":"Eur J Heart Fail"},{"key":"2229_CR33","doi-asserted-by":"publisher","first-page":"376","DOI":"10.14740\/cr1137","volume":"11","author":"K Tashiro","year":"2020","unstructured":"Tashiro K, Kuwano T, Ideishi A, Morita H, Idemoto Y, Goto M, et al. Sacubitril\/valsartan inhibits cardiomyocyte hypertrophy in angiotensin ii-induced hypertensive mice independent of a blood pressure-lowering effect. Cardiol Res. 2020;11:376\u201385.","journal-title":"Cardiol Res"},{"key":"2229_CR34","doi-asserted-by":"publisher","unstructured":"Suematsu Y, Tashiro K, Morita H, Ideishi A, Kuwano T, Miura S. Angiotensin receptor blocker and neprilysin inhibitor suppresses cardiac dysfunction by accelerating myocardial angiogenesis in apolipoprotein E-knockout mice fed a high-fat diet. J Renin Angiotensin Aldosterone Syst 2021:9916789. https:\/\/doi.org\/10.1155\/2021\/9916789.","DOI":"10.1155\/2021\/9916789"},{"key":"2229_CR35","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.116.024482","volume":"135","author":"DM Ryba","year":"2017","unstructured":"Ryba DM, Li J, Cowan CL, Russell B, Wolska BM, Solaro RJ. Long-term biased \u03b2-arrestin signaling improves cardiac structure and function in dilated cardiomyopathy. Circulation. 2017;135:1056\u201370.","journal-title":"Circulation"},{"key":"2229_CR36","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1093\/eurheartj\/ehx196","volume":"38","author":"PS Pang","year":"2017","unstructured":"Pang PS, Butler J, Collins SP, Cotter G, Davison BA, Ezekowitz JA, et al. Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). Eur Heart J. 2017;38:2364\u201373.","journal-title":"Eur Heart J"},{"key":"2229_CR37","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3390\/biomedicines11051486","volume":"11","author":"Y Matsuo","year":"2023","unstructured":"Matsuo Y, Suematsu Y, Morita H, Miura S. Development of a non-peptide angiotensin II Type 1 receptor ligand by structural modification of olmesartan as a biased agonist. Biomedicines. 2023;11:1486 https:\/\/doi.org\/10.3390\/biomedicines11051486.","journal-title":"Biomedicines"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02229-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02229-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02229-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:49:44Z","timestamp":1757173784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02229-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2229"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02229-5","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S.M. has ties to companies with COI relationships that should be disclosed in relation to the topic presented include; Lecture fees (Otsuka Pharmaceutical, Novartis Pharma, Daiichi Sankyo Co., Ltd.), commissioned research and joint research funds (AMGEN, Bayer Yakuhin, Novo Nordisk Pharma, MSD), and scholarship donations (Abbott, Sumitomo Pharma).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}